News – Page 983 – Endpoints News

Immunotherapy developer Enlivex uses Bioblast shell to reverse merge its way onto Nasdaq

7 years ago

FDA works to reduce dog testing in drug development

7 years ago

Leo Pharma lines up an option to buy BridgeBio's PellePharm and its PhIII rare skin cancer drug

7 years ago

Fortress Biotech sells brokerage firm following Reuters exposé; Tracon contends with another setback in brain cancer

7 years ago

Is AstraZeneca looking for the ideal candidate to replace Pascal Soriot?

7 years ago

Novartis-backed Inflazome raises $46M for their clinical challenge to prove NLRP3 is a great anti-inflammatory target

7 years ago

Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers

7 years ago

Pfizer, Merck KGaA report their latest setback with checkpoint contender Bavencio

7 years ago

Tesaro stock soars on another report the PARP player is exploring a sale

7 years ago

Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but ...

7 years ago

Undeterred by exec exodus, Immunocore nabs $100M cash to co-develop preclinical asset with Roche

7 years ago

Genfit plans US listing as NASH drugmakers race to the finish line

7 years ago

Pfizer preps a laundry list of drug price hikes for the New Year — let the political fireworks begin

7 years ago

While controversy over Brexit reaches full boil, a pharma trade group sees the upside in a draft deal

7 years ago

Takeda family preps for a last-stand vote against Shire buyout; Eli Lilly reportedly shopping drug portfolio in China

7 years ago

Japanese billionaire Mikitani takes full control of Rakuten Aspyrian; HOX Therapeutics taps Karl Keegan as CEO

7 years ago

Sanofi teams with non-profit on a landmark new drug for sleeping sickness

7 years ago

Eli Lilly partner Chi-Med sees shares tank as its newly approved cancer drug flunks PhIII lung cancer trial

7 years ago

AbbVie touts promising PhIII data for Orilissa as execs line up their second pitch and rivals lay in wait

7 years ago

With radiotherapy en vogue, Belgian startup nabs nearly $42M in Series A funding

7 years ago

AstraZeneca’s big MYSTIC trial ends a complete failure as Imfinzi/tremelimumab combo flops on overall survival

7 years ago

Bolstered by promising PhIIb snapshot, uniQure plays catch-up with Spark in the race to a hemophilia B gene therapy

7 years ago

Centrexion delays IPO; Exelixis makes $40M as Cabometyx wins EU nod

7 years ago

The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells

7 years ago

First page Previous page 980 981 982983984 985 986 Next page Last page